Personalized vaccine for recurrent ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a personalized cancer vaccine made from your own tumor cells. It is for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has returned after at least one round of platinum chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and female.
- You have advanced ovarian, primary peritoneal, or fallopian tube cancer (not carcinosarcoma) that has been treated with at least one round of platinum-based chemotherapy, and your doctor says a single drug is a good next step.
- Your cancer has come back or progressed after your most recent treatment.
- You have at least two spots of cancer that can be seen on scans, and you are willing to have a small piece of tumor (about 1 gram) removed for the vaccine.
- You are generally able to care for yourself (ECOG performance 0-2) and have recovered from side effects of prior treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine made from your tumor's genetic material. It is given after surgery to help your immune system recognize and attack any remaining cancer cells, with the goal of preventing the cancer from coming back.
This trial tests a personalized treatment using your own immune cells (called TILs) to fight ovarian cancer that has returned. After collecting and growing these cells, you receive chemotherapy and other drugs to help them work better.
This trial tests a new combination of treatments for advanced ovarian, fallopian tube, or peritoneal cancer. It combines chemotherapy and immunotherapy (drugs that help your immune system fight cancer) with a special vaccine made from your own tumor. The goal is to see if this approach is more effective than standard treatment.
This Phase 1 study tests whether giving your own immune cells—engineered to target the FSH receptor—can control recurrent ovarian-related cancers. It’s mainly looking at safety and early signs of activity for patients whose cancer has not responded well to standard platinum chemotherapy.
This trial tests a vaccine called CryptiVax-1001 for people with advanced ovarian cancer who have finished first-line chemotherapy and are in remission, as maintenance therapy. The goal is to see if the vaccine can help keep the cancer from coming back.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.